Castle Biosciences Q2 revenue $103.5M (+20% YoY); raises FY2026 guidance to $365-375M

CASTLE BIOSCIENCES INC

Q2 revenue $103.5M vs $86.2M YoY; net loss $2.1M (incl. $11.6M stock comp) vs net income $4.5M.
Core test reports (DecisionDx-Melanoma, TissueCypher) up 32% YoY; TissueCypher reports surged 63% to 14,988.
Raises FY2026 revenue guidance to $365-375M from $345-355M; expects positive Adjusted EBITDA in Q3, Q4, and full year.
Adjusted EBITDA $12.4M vs $10.4M; cash $266.8M.
AdvanceAD-Tx test received NYSDOH approval; first patient enrolled in DETECT-AD study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.